Muthusamy Shanmugam Sells 7,414 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam sold 7,414 shares of the stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $66.33, for a total value of $491,770.62. Following the sale, the chief operating officer now owns 825,206 shares of the company’s stock, valued at $54,735,913.98. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Muthusamy Shanmugam also recently made the following trade(s):

• On Wednesday, April 17th, Muthusamy Shanmugam sold 9,520 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.40, for a total value of $622,608.00.
• On Thursday, March 7th, Muthusamy Shanmugam sold 15,085 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $66.35, for a total value of $1,000,889.75.
• On Tuesday, March 5th, Muthusamy Shanmugam sold 10,093 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.35, for a total value of $659,577.55.
• On Monday, January 22nd, Muthusamy Shanmugam sold 5,692 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $55.95, for a total value of $318,467.40.
• On Thursday, January 18th, Muthusamy Shanmugam sold 9,784 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $55.30, for a total value of $541,055.20.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP opened at $65.48 on Friday. ANI Pharmaceuticals, Inc. has a fifty-two week low of $36.99 and a fifty-two week high of $70.81. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of 77.95 and a beta of 0.79. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.81 and a current ratio of 3.57. The firm’s 50-day simple moving average is $64.95 and its 200 day simple moving average is $58.63.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. The business had revenue of $131.65 million for the quarter, compared to analysts’ expectations of $123.02 million. As a group, research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.55 earnings per share for the current fiscal year.

Analyst Ratings Changes

ANIP has been the topic of a number of research analyst reports. HC Wainwright increased their price objective on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a “buy” rating in a research report on Monday, March 4th. Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Guggenheim increased their price objective on shares of ANI Pharmaceuticals from $70.00 to $77.00 and gave the stock a “buy” rating in a research report on Tuesday, March 5th. Finally, Capital One Financial initiated coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 15th. They set an “overweight” rating and a $80.00 price objective on the stock. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $80.00.

Hedge Funds Weigh In On ANI Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. increased its stake in ANI Pharmaceuticals by 93.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 248 shares during the last quarter. BluePath Capital Management LLC purchased a new stake in ANI Pharmaceuticals in the 3rd quarter valued at about $34,000. Pacer Advisors Inc. purchased a new stake in ANI Pharmaceuticals in the 4th quarter valued at about $41,000. Point72 Asset Management L.P. increased its stake in ANI Pharmaceuticals by 60.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 776 shares of the specialty pharmaceutical company’s stock valued at $42,000 after buying an additional 291 shares during the last quarter. Finally, Coppell Advisory Solutions LLC purchased a new stake in ANI Pharmaceuticals in the 2nd quarter valued at about $44,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.